Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency

Area of Science:

• Genetics and Molecular Biology
• Pulmonology
• Hepatology

Background:

• Alpha-1 antitrypsin deficiency (AAT) is an inherited disorder resulting from AAT gene mutations.
• It leads to low plasma AAT levels, increasing risk for early pulmonary emphysema and liver damage.
• Augmentation therapy using human plasma-derived AAT has been available since the late 1980s.

Purpose of the Study:

• To evaluate the safety and efficacy of individualized AAT augmentation therapy regimens.
• To determine optimal administration intervals for maintaining protective serum AAT levels.
• To address the underdiagnosis of AAT deficiency and improve patient identification.

Main Methods:

• Pharmacokinetic studies were conducted to assess AAT serum concentrations.
• Therapeutic regimens with varying infusion frequencies were analyzed.
• Analysis of data from national and international registries for AAT deficiency.

Main Results:

• Weekly intravenous AAT infusions are safe and achieve protective lung AAT concentrations.
• Bi-weekly AAT administration is safe and maintains adequate trough serum AAT levels.
• Less frequent administrations result in sub-therapeutic AAT trough levels.

Conclusions:

• Individualizing AAT augmentation therapy to bi-weekly intervals may improve patient adherence.
• Less frequent AAT administration than bi-weekly is insufficient for maintaining protective levels.
• Establishing patient registries is crucial for increasing disease awareness and facilitating clinical trials.